Table 2

Median time and time to the 25th percentile to initial and continued pain improvement from baseline in patients with PsA receiving tofacitinib 5 mg BID or placebo-to-tofacitinib 5 mg BID (pooled across OPAL Broaden and OPAL Beyond); tofacitinib 5 mg BID, placebo-to-tofacitinib 5 mg BID or adalimumab 40 mg Q2W (OPAL Broaden only)

Pooled across OPAL Broaden and OPAL BeyondOPAL Broaden
Tofacitinib 5 mg BID (N=236)Placebo→tofacitinib
5 mg BID at month 3
(N=118)
Log-rank test,
p value*
Tofacitinib 5 mg BID (N=107)Adalimumab
40 mg Q2W
(N=105)
Placebo→tofacitinib
5 mg BID at month 3
(N=52)
Log-rank test,
p value (tofacitinib)*
Log-rank test,
p value (adalimumab)*
Time to ≥30% pain improvement, days (95% CI)
Initial improvement
Median55.0 (29.0 to 57.0)106.0 (64.0 to 115.0)0.013257.0 (29.0 to 57.0)29.0 (17.0 to 57.0)113.0 (57.0 to 169.0)0.04650.011
25th percentile15.0 (15.0 to 16.0)29.0 (15.0 to 37.0)15.0 (15.0 to 28.0)15.0 (NE)19.0 (15.0 to 57.0)
Continued improvement
Median60.0 (57.0 to 85.0)126.0 (113.0 to 173.0)0.006764.0 (57.0 to 113.0)57.0 (29.0 to 85.0)168.0 (112.0 to 252.0)0.17910.045
25th percentile16.0 (15.0 to 28.0)58.0 (29.0 to 106.0)18.0 (15.0 to 33.0)15.0 (15.0 to 17.0)47.0 (15.0 to 112.0)
Time to ≥50% pain improvement, days (95% CI)
Initial improvement
Median85.0 (57.0 to 92.0)169.0 (120.0 to 189.0)0.006864.0 (57.0 to 92.0)57.0 (29.0 to 157.0)171.0 (113.0 to 253.0)0.03280.1028
25th percentile29.0 (27.0 to 31.0)57.0 (29.0 to 106.0)29 (20.0 to 31.0)26 (15.0 to 29.0)57 (15.0 to 113.0)
Continued improvement
Median171.0 (90.0–NE)NE (247.0–NE)0.005176.0 (85.0–NE)169.0 (60.0–NE)253.0 (169.0–NE)0.28920.1991
25th percentile51.0 (29.0 to 57.0)115.0 (88.0 to 169.0)56.0 (28.5 to 58.0)29.0 (15.0 to 56.0)113.0 (29.0 to 169.0)
  • Median time to initial/continued improvement was estimated via a non-parametric Kaplan-Meier method.

  • ‘Initial’ improvement was defined as the first post-baseline day with a pain improvement of ≥30% or ≥50% relative to baseline. ‘Continued’ improvement was defined as the first post-baseline visit where there was pain improvement of ≥30% or ≥50% relative to baseline that was maintained up to the next visit (ie, two consecutive observations).

  • *Versus placebo switching to tofacitinib 5 mg BID at month 3.

  • BID, twice daily; N, total number of patients in that group; NE, not estimable, as the time was beyond duration of the study; PsA, psoriatic arthritis; Q2W, once every 2 weeks.